. 2022 Mar 3;22:55. doi: 10.1186/s12905-022-01627-y

Table 2.

Synthesis of data about general features and eligibility criteria of study population treated with MRgHIFU

#	References	Study design	Mean age	Number of patients	Number of FB	Inclusion criteria	Exclusion criteria	Mean volume of treated FB	Fibroid shrinkage (%)	Follow up period (months)
1	Hindley et al. [23]	PRO	45	109	NM	Age > 18, b	f, g, h, i, l, m, n	346 ± 245 cm³ (single) 294 ± 188 cm³ (multiple)	13.5	6
2	Mikami et al. [24]	RETR	44	48	NM	a, b	e, q	NM	23	6
3	Morita et al. [25]	PRO	43	48	55	Age > 18, b, o	d, i, n, m, s	NM	33 ± 19	6
4	Rabinovici et al. [26]	PRO	46	35	41	a, l	k (20 w), j (10 cm), g, h	216 ± 223 ml	15 ± 27	6
5	Lánä́rd et al. [27]	RETR	45	66	NM	Age > 18, a, b, o	f, g, h, i, l, m, n	255.5 ± 201.7 cm³	12.6 ± 16.9	6
5	Lánä́rd et al. [27]	RETR	45	66	NM	Age > 18, a, b, o	f, g, h, i, l, m, n	255.5 ± 201.7 cm³	9.3 ± 24.8	12
6	Zhang et al. [28]	PRO	39	21	23	Age > 18, a, e, o	j (10 cm), g, h, u	77.3 ± 66.6 cm³	31.4 ± 29.3	3
7	Funaki et al. [29]	PRO	40	91	141	–	f, g, h, i, n, p, s, t	NM	33.1	6
									38	12
									38.2	24
8	Kim et al. [30]	PRO	46	40	51	Age > 18, a, o	c, e, f, g, h, i, k	336 ± 40.8 cm³	18.7	6
									25.8	12
									27.6	24
9	Ruhnke et al. [31]	PRO	47 ± 4	18	27	Age 18–59, a, o	c, f, g, h, i, q, w	125 ± 140 ml	45 ± 21	6
10	Thiburce et al. [32]	RETR	44	36	NM	Age > 18, o	f, j, n, r, q	255 (190–319) cm³	27	6
11	Tung et al. [33]	PRO	42	40	NM	–	j (10 cm), f, n	258.1 ± 223.8 cm³	31.7	6
12	Xu [34]	PRO	42	43	51	Age 18–55, a, b, o	j (12 cm), h, q	NM	33.51	3
12	Xu [34]	PRO	42	43	51	Age 18–55, a, b, o	j (12 cm), h, q	NM	44.52	6
13	Chen et al. [35]	PRO	45	107	130	Age > 18, o, m < 140 kg, l	n, g, l, h	NM	41.6 ± 22.70	3
13	Chen et al. [35]	PRO	45	107	130	Age > 18, o, m < 140 kg, l	n, g, l, h	NM	50.2 ± 20.40	6
14	Jacoby et al. [36]	PRO	44	13	NM	Age > 18, a, o, b	g, l, h, u, v, j (10 cm),	217 ± 139	18	6
15	Keserci et al. [37]	PRO	40	120	339	Age > 18, a, o	n, g, s, u, h	197.3 ± 155.7 ml	38 ± 26	6

NM, not mentioned, FB, fibroid; PRO, prospective case series; RETR, retrospective case series

a- fibroid related disease; b- no desire for further pregnancies; c- conceive after MRgFUS; d- 3 months treatment GnRH analogue; e- bowel lies anterior to the uterus; f- abdominal scar (locate in the path of the ultrasound beam); g- pregnancy; h- contraindications to MRI and Gadolinium use; i- major medical disease; j- fibroid diameter > 15 cm, k- Uterus larger than 24 gestational weeks, l- hematocrit less than 25%; m- postmenopause; n- other pelvic diseases; o- premenopause; p-lactating; q- degeneration or calcification of fibroids; r- submucosal fibroids, s- pelvic inflammatory disease, t- abnormal coagulation status, u- malignancy, v- abnormal endometrial biopsy results, w- abnormal PAP test